211 related articles for article (PubMed ID: 25604120)
1. Environmental enteropathy and malnutrition: do we know enough to intervene?
Petri WA; Naylor C; Haque R
BMC Med; 2014 Oct; 12():187. PubMed ID: 25604120
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
Jones KD; Hünten-Kirsch B; Laving AM; Munyi CW; Ngari M; Mikusa J; Mulongo MM; Odera D; Nassir HS; Timbwa M; Owino M; Fegan G; Murch SH; Sullivan PB; Warner JO; Berkley JA
BMC Med; 2014 Aug; 12():133. PubMed ID: 25189855
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response.
Gilmartin AA; Petri WA
Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1671):. PubMed ID: 25964455
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Study of Environmental Enteropathy and Malnutrition (SEEM) in Pakistan: protocols for biopsy based biomarker discovery and validation.
Iqbal NT; Syed S; Sadiq K; Khan MN; Iqbal J; Ma JZ; Umrani F; Ahmed S; Maier EA; Denson LA; Haberman Y; McNeal MM; Setchell KDR; Zhao X; Qureshi S; Shen L; Moskaluk CA; Liu TC; Yilmaz O; Brown DE; Barratt MJ; Kung VL; Gordon JI; Moore SR; Ali SA
BMC Pediatr; 2019 Jul; 19(1):247. PubMed ID: 31331393
[TBL] [Abstract][Full Text] [Related]
6. Mesalazine. Now authorised for children, but no suitable form.
Prescrire Int; 2011 Sep; 20(119):208. PubMed ID: 21954515
[No Abstract] [Full Text] [Related]
7. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
8. Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh.
Naylor C; Lu M; Haque R; Mondal D; Buonomo E; Nayak U; Mychaleckyj JC; Kirkpatrick B; Colgate R; Carmolli M; Dickson D; van der Klis F; Weldon W; Steven Oberste M; ; Ma JZ; Petri WA
EBioMedicine; 2015 Nov; 2(11):1759-66. PubMed ID: 26870801
[TBL] [Abstract][Full Text] [Related]
9. Environmental enteropathy.
Ali A; Iqbal NT; Sadiq K
Curr Opin Gastroenterol; 2016 Jan; 32(1):12-7. PubMed ID: 26574871
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory bowel disease and drug intake.
Roberta P; Antonino B; Paolo P
Inflamm Bowel Dis; 2005 Oct; 11(10):951. PubMed ID: 16189429
[No Abstract] [Full Text] [Related]
12. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules.
Marteau P; Tennenbaum R; Elefant E; Lémann M; Cosnes J
Aliment Pharmacol Ther; 1998 Nov; 12(11):1101-8. PubMed ID: 9845399
[TBL] [Abstract][Full Text] [Related]
13. Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy.
Rácz I; Szalai M; Kovács V; Regőczi H; Kiss G; Horváth Z
World J Gastroenterol; 2013 Feb; 19(6):889-96. PubMed ID: 23431027
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
Wiersma H; Escher JC; Dilger K; Trenk D; Benninga MA; van Boxtel CJ; Taminiau J
Inflamm Bowel Dis; 2004 Sep; 10(5):626-31. PubMed ID: 15472525
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease.
Matsumoto S; Mashima H
Sci Rep; 2020 Dec; 10(1):22176. PubMed ID: 33335169
[TBL] [Abstract][Full Text] [Related]
17. The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
Kadiyala I; Jacobs D
Recent Pat Drug Deliv Formul; 2014 Apr; 8(1):3-11. PubMed ID: 24111938
[TBL] [Abstract][Full Text] [Related]
18. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
Osterman MT; Lichtenstein GR
Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
[TBL] [Abstract][Full Text] [Related]
19. Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial.
Cheng WD; Wold KJ; Benzoni NS; Thakwalakwa C; Maleta KM; Manary MJ; Trehan I
Trials; 2017 Nov; 18(1):523. PubMed ID: 29110675
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
